Diffuse Alveolar Hemorrhage After Infliximab Treatment of Crohnʼs Disease
Open Access
- 1 May 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 10 (3) , 274-277
Abstract
Infliximab (Remicade), a chimeric monoclonal antibody to tumor necrosis factor-alpha (anti–TNF-α), is being used with increasing frequency in the treaKeywords
This publication has 9 references indexed in Scilit:
- Delayed Hypersensitivity Reaction and Acute Respiratory Distress Syndrome Following Infliximab InfusionInflammatory Bowel Diseases, 2002
- CASE REPORT: Crohn's Disease Involving the LungDigestive Diseases and Sciences, 2001
- The relationship between infliximab treatment and lymphoma in Crohn's diseaseGastroenterology, 1999
- Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseGastroenterology, 1999
- Review article: safety of infliximab in clinical trialsAlimentary Pharmacology & Therapeutics, 1999
- Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease: A Review of Agents, Pharmacology, Clinical Results, and SafetyInflammatory Bowel Diseases, 1999
- PULMONARY PATHOLOGY IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASESClinics in Chest Medicine, 1998
- Infliximab Approved for Use in Crohnʼs Disease: A Report on the FDA GI Advisory Committee ConferenceInflammatory Bowel Diseases, 1998
- Metastatic Crohn's Disease of the LungJournal of Pediatric Gastroenterology and Nutrition, 1998